Please find attached Press Release on Unaudited Financial Results for the quarter ended 30th June, 2026.

Date: 4th August, 2026 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 533573 NSE Symbol: APLLTD Dear Sir/Madam, Sub: Press Release on the Unaudited Financial Results for the quarter ended 30th June, 2026. With reference to the captioned subject, please find enclosed herewith the Press Release on the Unaudited Financial Results of the Company for the quarter ended 30th June, 2026. We request you to kindly take the same on record. Thanking you, Yours faithfully, For Alembic Pharmaceuticals Limited Manisha Saraf Company Secretary Encl.: A/a. ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123 Press Release Alembic Pharmaceuticals reports resilient Q1 FY27 performance Revenue up 26%; EBITDA up 21% YoY Vadodara, August 4th, 2026: Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter and year ended 30th June 2026. Financial Highlights for Q1 FY26  Revenue from operations increased by 26% YoY to Rs.2150 Cr.  Profit After Tax at Rs. 173 Cr, up 12% YoY  EBITDA pre R&D increased to Rs. 523 Cr; margin stood at 24% Commenting on the results, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said, “We have started FY27 on a strong note, delivering broad-based growth across our businesses. Performance during the quarter was driven by healthy volume growth, successful new product launches and continued execution across key markets. The US business delivered strong momentum, and the rest of the markets also recorded steady growth. We remain focused on strengthening our product portfolio, advancing our pipeline and driving sustainable long-term growth.” Operational Highlights India Branded Business  India Branded Business delivered 7% YoY growth, reaching Rs 642 Cr. in revenue for the quarter.  Gynaecology, Gastrology and Ophthalmology have shown robust growth.  Animal healthcare segment delivered encouraging performance during the quarter.  3 new products were introduced during the quarter. ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123 International Business  US Formulation grew by 49% to Rs. 778 Cr.  7 Launches in the US market during the quarter.  Ex-US Generics grew by 17% to Rs. 383 Cr.  10 ANDA approvals received during the quarter API Business  API business grew by 33% to Rs. 346 Cr. The summary of Revenue from Operations is as under: (Rs in Cr.) Q1 Q1 % Change Particulars FY26 FY27 Formulation India 5 9 9 642 7% USA 523 778 49% Ex- US 328 383 17% API 261 346 33% Total 1711 2150 26% Earnings Call: Alembic Pharmaceuticals Limited will host an investor call at 5.30 pm IST on August 04, 2026, where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1411/ +91 22 7115 8312. Other toll numbers are listed in the conference call invitation, which is posted on the Company website www.alembicpharmaceuticals.com. The operator will provide instructions on asking questions before the start of the call. ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123 About Alembic Pharmaceuticals Limited Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573) For more information, contact: Isha Lamba: Phone: +91 022- 66951652 Email: isha.lamba@alembic.co.in ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123